The TARGET BP OFF-MED Trial
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Ablative Solutions, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT03503773
- Locations
- 🇬🇧
NIHR Barts Cardiovascular Biomedical Research Unit, London, United Kingdom
🇩🇪Universitätsklinikum des Saarlandes, Homburg/Saar, Germany
🇫🇷Clinique Pasteur Toulouse, Toulouse, France
TARGET BP I Clinical Trial
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Ablative Solutions, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT02910414
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸NC Heart and Vascular Research, Raleigh, North Carolina, United States
The Peregrine Post-Market Study for the Treatment of Hypertension
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Ablative Solutions, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02570113
- Locations
- 🇵🇱
Oddizal Kardiologiczno-Angiologiczny PAKS, Ustron, Poland
🇵🇱Oddzial Kardiologii Inwazyjnej, Tychy, Poland
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
The Peregrine Study: A Safety and Performance Study of Renal Denervation
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Ablative Solutions, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02155790
- Locations
- 🇵🇱
American Heart of Poland, Ustron, Poland
🇨🇿Na Homolce Hospital, Prague, Czechia
© Copyright 2024. All Rights Reserved by MedPath